Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Characterization of reverse-engineered anti-PF4 stereotypic antibodies derived from serum of patients with VITT

Blood (2024) 143 (4): 370–374.

https://doi.org/10.1182/blood.2023021307

Published: 2024

Includes: Supplemental data

Journal Articles

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure

Blood (2023) 142 (26): 2305–2314.

https://doi.org/10.1182/blood.2023022136

Published: 2023

Includes: Supplemental data

Journal Articles

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Michael L. Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, Shazia K. Nakhoda, Julio C. Chavez, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Wahib Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 734.

https://doi.org/10.1182/blood-2023-174956

Published: 2023

Journal Articles

Real World Favourable Experience of Haematopoietic Stem Cell Transplantation during Acute Coronavirus Disease 2019 in a Highly-Vaccinated Asian Population

Christopher Tham, Yeh Ching Linn, Lawrence Ng, Jeffrey Quek, Aloysius YL Ho, Francesca Lim, Yunxin Chen, William YK Hwang, Jing Jing Lee, Gina Gan, Jasmine Shimin Chung, Ban Hock Tan, Thuan Tong Tan, Hein Than

Blood (2022) 140 (Supplement 1): 12850–12851.

https://doi.org/10.1182/blood-2022-165079

Published: 2022

Journal Articles

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jason Westin, Adam J. Olszewski, Laura Maria Fogliatto, Won-Seog Kim, Ho-Jin Shin, Hao Wu, Shen Yin, Song Pham, Elicia Penuel, Jing Jing, Michael C. Wei, Elizabeth L. Budde

Blood (2022) 140 (Supplement 1): 3771–3772.

https://doi.org/10.1182/blood-2022-157710

Published: 2022

Journal Articles

Vaccine-induced immune thrombotic thrombocytopenia is mediated by a stereotyped clonotypic antibody

Jing Jing Wang, Bridie Armour, Tim Chataway, Alexander Troelnikov, Alex Colella, Olivia Yacoub, Simon Hockley, Chee Wee Tan, Tom Paul Gordon

Blood (2022) 140 (15): 1738–1742.

https://doi.org/10.1182/blood.2022016474

Published: 2022

Includes: Supplemental data

Journal Articles

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Thomas E. Witzig, Craig Reeder, Jing Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir Markovic, Grzegorz S. Nowakowski, Mamta Gupta

Blood (2015) 126 (3): 328–335.

https://doi.org/10.1182/blood-2015-02-629543

Published: 2015

Includes: Supplemental data

Journal Articles

Ventricular Assist Devices and Extracorporeal Membrane Oxygenation Devices Are Associated with Loss of Platelet Receptors

Pohan Lukito, MBBS, B MDSci, Angus K.T Wong, MBBS, B MDSci, Jing Jing, Jane F Arthur, PhD, Elizabeth E. Gardiner, PhD, Robert K Andrews, PhD, Amanda K. Davis, MBBS, FRACP, FRCPA

Blood (2014) 124 (21): 5001.

https://doi.org/10.1182/blood.V124.21.5001.5001

Published: 2014

Journal Articles

Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells

Mamta Gupta, Ph.D, Jing Jing Han, Mary Stenson, B.S, Linda E Wellik, Thomas E Witzig, MD

Blood (2013) 122 (21): 636.

https://doi.org/10.1182/blood.V122.21.636.636

Published: 2013

Journal Articles

In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy

Mamta Gupta, Ph.D, Matthew J. Maurer, MS, Mary Stenson, B.S, Linda E. Wellik, Jing Jing Han, Andrew L. Feldman, Thomas M. Habermann, MD, Thomas E. Witzig, MD

Blood (2013) 122 (21): 844.

https://doi.org/10.1182/blood.V122.21.844.844

Published: 2013

Journal Articles

SHP1 Suppression In Diffuse Large B Cell Lymphoma Is Regulated Through Promoter Hypermethylation At Novel CpG2 Island and H3K27 Trimethylation Histone Mark

Mamta Gupta, Ph.D, Guangzhen Hu, Linda E Wellik, Jing Jing Han, Mary Stenson, B.S, Ahmet Dogan, MD, PhD, Thomas E Witzig, MD

Blood (2013) 122 (21): 632.

https://doi.org/10.1182/blood.V122.21.632.632

Published: 2013

Journal Articles

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

Mamta Gupta, Matthew J. Maurer, Linda E. Wellik, Mark E. Law, Jing Jing Han, Nazan Ozsan, Ivana N. Micallef, Ahmet Dogan, Thomas E. Witzig

Blood (2012) 120 (22): 4400–4406.

https://doi.org/10.1182/blood-2012-05-428466

Published: 2012

Includes: Supplemental data

Journal Articles

Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP

Mamta Gupta, Ph.D, Matthew J Maurer, MS, Linda Wellik, Mark E Law, Jing Jing Han, Ivana N. Micallef, MD, Ahmet Dogan, MD, PhD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 1575.

https://doi.org/10.1182/blood.V120.21.1575.1575

Published: 2012

Journal Articles

Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.

Mamta Gupta, Ph.D, Guangzhen Hu, Steven Offer, Matthew J Maurer, MS, Linda Wellik, Jing Jing Han, Ahmet Dogan, MD, PhD, Robert B. Diasio, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2655.

https://doi.org/10.1182/blood.V120.21.2655.2655

Published: 2012

Journal Articles

Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels

Mohammad Al-Tamimi, Chee Wee Tan, Jianlin Qiao, Gabrielle J. Pennings, Ashkan Javadzadegan, Andy S. C. Yong, Jane F. Arthur, Amanda K. Davis, Jing Jing, Fi-Tjen Mu, Justin R. Hamilton, Shaun P. Jackson, Andreas Ludwig, Michael C. Berndt, Christopher M. Ward, Leonard Kritharides, Robert K. Andrews, Elizabeth E. Gardiner

Blood (2012) 119 (18): 4311–4320.

https://doi.org/10.1182/blood-2011-10-386607

Published: 2012

Journal Articles

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

Mamta Gupta, Jing Jing Han, Mary Stenson, Matthew Maurer, Linda Wellik, Guangzhen Hu, Steve Ziesmer, Ahmet Dogan, Thomas E. Witzig

Blood (2012) 119 (12): 2844–2853.

https://doi.org/10.1182/blood-2011-10-388538

Published: 2012

Includes: Supplemental data

Journal Articles

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Mamta Gupta, Andrea E. Wahner Hendrickson, Seong Seok Yun, Jing Jing Han, Paula A. Schneider, Brian D. Koh, Mary J. Stenson, Linda E. Wellik, Jennifer C. Shing, Kevin L. Peterson, Karen S. Flatten, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Sharon Barr, Thomas E. Witzig, Scott H. Kaufmann

Blood (2012) 119 (2): 476–487.

https://doi.org/10.1182/blood-2011-04-346601

Published: 2012

Includes: Supplemental data

Journal Articles

The Feature of CD3γ, CD3δ and CD3ε Gene Expression in Benzene-Exposed and Benzene- Poisoned Workers

Bo Li, Jing Jing Fan, Jing Ru Wang, Yun Yu Chen, Shao Hua Chen, Li Jian Yang, Yu Wei, Wei Wei Liu, Jia Yu Chen, Yang Qiu Li

Blood (2011) 118 (21): 4929.

https://doi.org/10.1182/blood.V118.21.4929.4929

Published: 2011

Journal Articles

Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation

Mamta Gupta, Ph.D, Mary Stenson, Jing Jing Han, Matthew J Maurer, MS, Linda Wellik, Steven C. Ziesmer, Ahmet Dogan, Thomas E. Witzig, MD

Blood (2011) 118 (21): 960.

https://doi.org/10.1182/blood.V118.21.960.960

Published: 2011

Journal Articles

Indirubin-3'-Monoxime Induces Apoptosis and Autophagy In Acute Lymphoblastic Leukemia Cells and Chronic Myelogenous Leukemia Cells, Exhibits Limited Cytotoxicity In CD34 + Hematopoietic Stem Cells, Lymphocytes and Granulocytes

Ming-Yang Lee, Yi-Wen Liu, Ming-Ho Chen, Jing-Jing Chuang

Blood (2010) 116 (21): 3984.

https://doi.org/10.1182/blood.V116.21.3984.3984

Published: 2010

NARROW

Characterization of reverse-engineered anti-PF4 stereotypic antibodies derived from serum of patients with VITT

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Real World Favourable Experience of Haematopoietic Stem Cell Transplantation during Acute Coronavirus Disease 2019 in a Highly-Vaccinated Asian Population

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Vaccine-induced immune thrombotic thrombocytopenia is mediated by a stereotyped clonotypic antibody

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Ventricular Assist Devices and Extracorporeal Membrane Oxygenation Devices Are Associated with Loss of Platelet Receptors

Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells

In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy

SHP1 Suppression In Diffuse Large B Cell Lymphoma Is Regulated Through Promoter Hypermethylation At Novel CpG2 Island and H3K27 Trimethylation Histone Mark

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP

Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.

Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

The Feature of CD3γ, CD3δ and CD3ε Gene Expression in Benzene-Exposed and Benzene- Poisoned Workers

Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation

Indirubin-3'-Monoxime Induces Apoptosis and Autophagy In Acute Lymphoblastic Leukemia Cells and Chronic Myelogenous Leukemia Cells, Exhibits Limited Cytotoxicity In CD34 + Hematopoietic Stem Cells, Lymphocytes and Granulocytes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only